Hite Biological: Injectable Itraconazole Drug Registration Certificate Approved

Hite Biological Announcement: the company has recently received the “Drug Registration Certificate” for injection isavuconazonium sulfate, which was approved and issued by the National Medical Products Administration. The drug is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients, and it is a Category B national medical insurance product. The company already has the qualification to sell this drug in the domestic market. It will further enrich the product portfolio and enhance competitiveness in the anti-infective field.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned